BrainStorm Cell Therapeutics Inc. (BCLI) - Cash per Single Share

Brainstorm Cell (BCLI) focuses on developing cellular treatments for ALS, protecting its niche through patents. The cash per share trend confirms financial stability, with the 0.00 mark recording this metric. Business development remains independent of economic cycles, relying instead on FDA verdicts. High-tech bioreactors support this stability, operating on a strict calibration schedule to eliminate product defects.
Comprehensive metric breakdowns and analytics for BrainStorm Cell Therapeutics (BCLI)

Cash per share dynamics reflect the financial stability of Brainstorm Cell (BCLI) as a biotech issuer. This metric determines the volume of liquid assets attributable to a single security. The calculation is based on the ratio of total cash balance to the number of shares outstanding. For a company in the intensive R&D phase of NurOwn, this indicator demonstrates the funding autonomy of clinical protocols. A sufficient liquidity reserve minimizes the risks of expensive borrowing.